Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Xilio Therapeutics (United States) | Researchclopedia

Back to institutions

Xilio Therapeutics (United States)

Waltham, Massachusettscompany

79

Works

7,906

Citations

64

h-index

Top Research Topics

Monoclonal and Polyclonal Antibodies Research CAR-T cell therapy research Cancer Immunotherapy and Biomarkers

Top Researchers

M. A. McLaughlin University of Wisconsin–Milwaukee

682 works38,912 citationsh-index: 91

Recent Research

The Emergence of Fentanyl + Medetomidine Overdose: Pharmacology, Toxicology, and Need for Poly-Drug Reversal Therapeutics

Robert B. Raffa,Eugene Vortsman,et al.

20260 citations

Immunotherapy and Immune Responses

Cancer Genomics and Diagnostics

Cytokine Signaling Pathways and Interactions

Peptidase Inhibition and Analysis

PARP inhibition in cancer therapy

Cancer Research and Treatments

Protein Structure and Dynamics

Psoriasis: Treatment and Pathogenesis

Cell Adhesion Molecules Research

Andrew Spencer The Alfred Hospital

839 works34,381 citationsh-index: 80

Edmund J. Lewis NKT Therapeutics (United States)

240 works27,896 citationsh-index: 71

Marcelo E. Bigal Ventix (Canada)

393 works24,274 citationsh-index: 80

Zhen Liu South China Agricultural University

505 works18,141 citationsh-index: 66

Bruce J. Dezube Xilio Therapeutics (United States)

293 works17,657 citationsh-index: 58

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Ezra Y. Rosen,Timothy A. Yap,et al.

20260 citations

A droplet microfluidics-based platform for generating target-specific, natively-paired immune libraries and identifying potent and developable antibodies

Anusuya Ramasubramanian,Brendan T. Deveney,et al.

20260 citations

P0023 Anti-TL1A and anti-IL-23 combination therapy is superior to its constituent monotherapies in mouse anti-CD40 colitis

M Siegel,D Giles,et al.

20260 citations

P0834 Interim Phase 1 Results for SPY003, a Novel Half-life Extended Monoclonal Antibody Targeting IL-23, Suggest a Potential for Q3M or Q6M Maintenance Dosing for Inflammatory Bowel Disease

Y Vugmeyster,R McLean,et al.

20260 citations

P0978 SKYLINE-UC: The First Platform Study in Ulcerative Colitis Assessing Efficacy and Safety of Three Long-Acting Antibodies Administered as Single Agents and in Combinations

S Danese,V Jairath,et al.

20260 citations